Ivivi Technologies, Inc. (Other) (8-K)
September 26 2007 - 4:08PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 25, 2007
IVIVI TECHNOLOGIES, INC.
(Exact Name of Registrant as Specified in Charter)
New Jersey 001-33088 22-2956711
---------- --------- ----------
(State Or Other Jurisdiction Of (Commission (IRS Employer
Incorporation) File Number) Identification No.)
|
224-S Pegasus Avenue, Northvale, NJ 07647
(Address of Principal Executive Offices)(Zip Code)
(201) 784-8168
Registrant's Telephone Number
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 7.01. REGULATION FD DISCLOSURE.
On September 25, 2007, Ivivi Technologies, Inc., a New Jersey
corporation (the "Company"), issued a press release pursuant to which the
Company announced that it received the initial order of 20,000 SofPulse(R)
devices from Allergan, Inc., its exclusive distribution partner for the
Company's SofPulse(R) line of products worldwide in the aesthetic and bariatric
medical procedure markets. A copy of the press release is being furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K under Item
7.01 is being furnished pursuant to Item 7.01 of Form 8-K. In accordance with
General Instruction B.2 of Form 8-K, the information in this Current Report on
Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section. The information in this Current
Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by
reference into any filing or other document pursuant to the Securities Act of
1933, as amended, except as shall be expressly set forth by specific reference
in such filing or document.
Forward Looking Statements
This Current Report on Form 8-K, including Exhibit 99.1,
contains forward-looking statements made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements typically are identified by use of terms such as "may," "will,"
"should," "plan," "expect," "anticipate," "estimate" and similar words, although
some forward-looking statements are expressed differently. Forward-looking
statements represent our management's judgment regarding future events. Although
the Company believes that the expectations reflected in such forward-looking
statements are reasonable, the Company can give no assurance that such
expectations will prove to be correct. All statements other than statements of
historical fact included in this Current Report on Form 8-K are forward-looking
statements. The Company cannot guarantee the accuracy of the forward-looking
statements, and you should be aware that the Company's actual results could
differ materially from those contained in the forward-looking statements due to
a number of factors, including the statements under "Risk Factors" contained in
the Company's Annual Report on Form 10-KSB filed with the Securities and
Exchange Commission.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
Exhibit 99.1 - Press release, dated September 25, 2007
(Exhibit 99.1 is furnished as part of
this Current Report on Form 8-K).
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
IVIVI TECHNOLOGIES, INC.
By: /s/ Andre' DiMino
-----------------
Name: Andre' DiMino
Title: Co-Chief Executive Officer
Date: September 26, 2007
|
3
Equifin (AMEX:II)
Historical Stock Chart
From Aug 2024 to Sep 2024
Equifin (AMEX:II)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Ivivi Technologies, Inc. (American Stock Exchange): 0 recent articles
More Ivivi Technologies, Inc. News Articles